{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:50:57Z","timestamp":1787755857028,"version":"build-2784847793"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03346-2","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:31:38Z","timestamp":1787747498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1457-4366","authenticated-orcid":false,"given":"Nizameddin","family":"Koca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-8248","authenticated-orcid":false,"given":"Seyit","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-0766","authenticated-orcid":false,"given":"Yasin","family":"\u015eahint\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-5123","authenticated-orcid":false,"given":"Hamit","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-0211","authenticated-orcid":false,"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-6273","authenticated-orcid":false,"given":"RalphA.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"3","key":"3346_CR1","first-page":"101","volume":"10","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Clinical Diabetol. 2009;10(3):101\u201328.","journal-title":"Clinical Diabetol"},{"key":"3346_CR2","doi-asserted-by":"crossref","unstructured":"GRADE Study Research Group. 2022 Glycemia reduction in type 2 diabetes\u2014glycemic outcomes. New England J Med. 22:387 12 1063-74.","DOI":"10.1056\/NEJMoa2200433"},{"issue":"1","key":"3346_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12933-021-01281-y","volume":"20","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Del Prato S, Schechter M, Leiter LA, Ceriello A, DeFronzo RA, et al. From glucose lowering agents to disease\/diabetes modifying drugs: a \u201cSIMPLE\u201d approach for the treatment of type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):92.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"3346_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"3346_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"3346_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"16","key":"3346_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"3346_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"key":"3346_CR9","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. 2023 Empagliflozin in patients with chronic kidney disease. N Engl J Med. 388 2 117\u201327.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"11","key":"3346_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"2","key":"3346_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8): a randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"24","key":"3346_CR12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"10516","key":"3346_CR13","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"JE Deanfield","year":"2025","unstructured":"Deanfield JE, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257\u201368.","journal-title":"Lancet"},{"issue":"20","key":"3346_CR14","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"issue":"2","key":"3346_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"21","key":"3346_CR16","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"3346_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"3","key":"3346_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"3346_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. Triple-hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"issue":"24","key":"3346_CR20","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409\u201320.","journal-title":"N Engl J Med"},{"key":"3346_CR21","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-0298","author":"N Sattar","year":"2026","unstructured":"Sattar N, Gerstein HC, D\u2019Alessio D, et al. Estimating the true MACE benefits from tirzepatide in SURPASS-CVOT using an imputed placebo analysis of REWIND. Diabetes Care. 2026. https:\/\/doi.org\/10.2337\/dc26-0298. ([Epub ahead of print]).","journal-title":"Diabetes Care"},{"issue":"7","key":"3346_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S2213-8587(26)00032-X","volume":"14","author":"S Zoungas","year":"2026","unstructured":"Zoungas S, D\u2019Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol. 2026;14(7):544\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3346_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"4","key":"3346_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"key":"3346_CR25","unstructured":"Eli Lilly and Company. Lilly\u2019s triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial: TRIUMPH-1 topline results. 21 May 2026."},{"issue":"14","key":"3346_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321\u201331.","journal-title":"N Engl J Med"},{"issue":"9493","key":"3346_CR27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"5","key":"3346_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus. Ann Intern Med. 2016;165(5):305\u201315.","journal-title":"Ann Intern Med"},{"issue":"11","key":"3346_CR29","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2337\/dc23-0872","volume":"46","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Vazquez L, Del Prato S, et al. Achieving normoglycemia with tirzepatide: analysis of SURPASS 1\u20134 trials. Diabetes Care. 2023;46(11):1986\u201392.","journal-title":"Diabetes Care"},{"issue":"10120","key":"3346_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"MEJ Lean","year":"2018","unstructured":"Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541\u201351.","journal-title":"Lancet"},{"issue":"5","key":"3346_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2\u00a0year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3346_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes (EDICT). Diabetes Obes Metab. 2015;17(3):268\u201375.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"3346_CR33","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/dom.14153","volume":"22","author":"M Abdul-Ghani","year":"2020","unstructured":"Abdul-Ghani M, Migahid O, Megahed A, DeFronzo RA, Al-Ozairi E, Jayyousi A. Combination therapy with pioglitazone\/exenatide improves beta-cell function and produces superior glycaemic control compared with basal\/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study. Diabetes Obes Metab. 2020;22(12):2287\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"3346_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41581-026-01066-0","volume":"22","author":"H Zaitoon","year":"2026","unstructured":"Zaitoon H, Abdul-Ghani M, DeFronzo RA. Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects. Nat Rev Nephrol. 2026;22(7):474\u201386.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"3346_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S2213-8587(24)00127-X","volume":"12","author":"M Abdul-Ghani","year":"2024","unstructured":"Abdul-Ghani M, Maffei P, DeFronzo RA. Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes. Lancet Diabetes Endocrinol. 2024;12(9):674\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"3346_CR36","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2337\/diab.41.12.1575","volume":"41","author":"G Gulli","year":"1992","unstructured":"Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes. 1992;41(12):1575\u201386.","journal-title":"Diabetes"},{"issue":"24","key":"3346_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124912","volume":"3","author":"D Tric\u00f2","year":"2018","unstructured":"Tric\u00f2 D, Natali A, Arslanian S, Mari A, Ferrannini E. Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents. JCI Insight. 2018;3(24):e124912.","journal-title":"JCI Insight"},{"issue":"10","key":"3346_CR38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/BF00400466","volume":"37","author":"S Del Prato","year":"1994","unstructured":"Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025\u201335.","journal-title":"Diabetologia"},{"issue":"12","key":"3346_CR39","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.17305\/bb.2025.12203","volume":"25","author":"Q Ge","year":"2025","unstructured":"Ge Q, Zhang F, Liu Y. Effect of SGLT2 inhibitors on liver fat content: a meta-analysis. Biomol Biomed. 2025;25(12):2647\u201357.","journal-title":"Biomol Biomed"},{"issue":"5","key":"3346_CR40","first-page":"846","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Sattar N, Pop-Busui R, et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2025;48(5):846\u201359.","journal-title":"Diabetes Care"},{"issue":"10489","key":"3346_CR41","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580\u201393.","journal-title":"Lancet"},{"issue":"13","key":"3346_CR42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"issue":"7","key":"3346_CR43","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1056\/NEJMoa2502082","volume":"393","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. 2025;393(7):648\u201359.","journal-title":"N Engl J Med"},{"issue":"10","key":"3346_CR44","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958\u201371.","journal-title":"N Engl J Med"},{"issue":"15","key":"3346_CR45","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"11","key":"3346_CR46","first-page":"4059","volume":"81","author":"K Cusi","year":"1996","unstructured":"Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81(11):4059\u201367.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3346_CR47","first-page":"89","volume":"6","author":"K Cusi","year":"1998","unstructured":"Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 1998;6(2):89\u2013131.","journal-title":"Diabetes Rev"},{"issue":"10208","key":"3346_CR48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","volume":"394","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Pald\u00e1nius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519\u201329.","journal-title":"Lancet"},{"issue":"14","key":"3346_CR49","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"3346_CR50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"3346_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"3","key":"3346_CR52","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/dc24-1773","volume":"48","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Tuttle KR, Pavo I, et al. Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from SURPASS-1-5. Diabetes Care. 2025;48(3):430\u20136.","journal-title":"Diabetes Care"},{"issue":"7","key":"3346_CR53","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037\u201348.","journal-title":"Nat Med"},{"key":"3346_CR54","unstructured":"Eli Lilly and Company. Lilly\u2019s triple agonist retatrutide successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. 23 July 2026."},{"issue":"4","key":"3346_CR55","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1210\/jc.2009-0911","volume":"95","author":"M Bajaj","year":"2010","unstructured":"Bajaj M, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(4):1916\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3346_CR56","doi-asserted-by":"publisher","first-page":"E871","DOI":"10.1152\/ajpendo.00551.2006","volume":"292","author":"A Gastaldelli","year":"2007","unstructured":"Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292(3):E871\u201383.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"3346_CR57","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","volume":"87","author":"Y Miyazaki","year":"2002","unstructured":"Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87(6):2784\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3346_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijcard.2011.09.039","volume":"162","author":"W Doehner","year":"2012","unstructured":"Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2012;162(1):20\u20136.","journal-title":"Int J Cardiol"},{"issue":"3","key":"3346_CR59","doi-asserted-by":"publisher","first-page":"e252577","DOI":"10.1001\/jamanetworkopen.2025.2577","volume":"8","author":"JX Li","year":"2025","unstructured":"Li JX, Hsu TJ, Lin HJ, et al. Combination of glucagon-like peptide 1 receptor agonist and thiazolidinedione for mortality and cardiovascular outcomes in patients with type 2 diabetes. JAMA Netw Open. 2025;8(3):e252577.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3346_CR60","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3346_CR61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, K\u00e4r\u00e4j\u00e4m\u00e4ki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10271","key":"3346_CR62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","volume":"397","author":"G Mingrone","year":"2021","unstructured":"Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293\u2013304.","journal-title":"Lancet"},{"issue":"7","key":"3346_CR63","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049\u201357.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"3346_CR64","first-page":"S1","volume":"49","author":"ADAPP Committee","year":"2026","unstructured":"Committee ADAPP. Standards of Care in Diabetes\u20142026. Diabetes Care. 2026;49(Suppl 1):S1\u2013326.","journal-title":"Diabetes Care"},{"issue":"10157","key":"3346_CR65","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes). Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"11","key":"3346_CR66","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388.","journal-title":"Diabetes Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03346-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03346-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03346-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:02:05Z","timestamp":1787752925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03346-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3346"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03346-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.K., S.U., Y.\u015e., H.Y., and R.A.D. declare no competing interests. S.D.P. reports consulting fees from Abbott, Altimmune, Applied Therapeutics, Biomea Fusion, Eli Lilly and Company, Menarini International, Hoffman-La Roche, Novo Nordisk, and Sun Pharma; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Menarini International, Novo Nordisk, and Sanofi.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"259"}}